Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Certican Filed in Japan for Liver Transplant Rejection: Novartis
April 28, 2017
- Daiichi Sankyo to More than Triple ADC Production Capacities by 2021
April 28, 2017
- Kyowa Kirin Submits Regpara Successor in Japan
April 28, 2017
- Astellas Looking to Xtandi Growth Outside US: President
April 28, 2017
- Astellas Sales Dip 4.4% on Forex Moves, Japan Biz Dented by Price Cuts
April 28, 2017
- Otsuka, Akebia Expand Licensing Pact for Anemia Med Vadadustat
April 27, 2017
- Nippon Kayaku to Codevelop Celltrion’s Rituxan Biosimilar
April 27, 2017
- Janssen Files Japan NDA for Multidrug-Resistant TB Drug
April 26, 2017
- Humira Filed for Pustular Psoriasis in Japan: AbbVie
April 26, 2017
- Mundipharma Japan Chief Voices Eagerness on Rare Cancer Therapies
April 25, 2017
- Kissei Ditches Dry Eye Med KCT-0809
April 25, 2017
- Lumicef PIII Kicks In for Axial Spondyloarthritis: Kyowa Kirin
April 25, 2017
- Drug Costs Can’t Be Curbed with Uniform Pricing of Gx, LLPs: Teva Takeda CEO
April 24, 2017
- With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
April 24, 2017
- Janssen’s Sirukumab Exhibits Significant Improvements in Primary Endpoints in Japanese PIII Studies
April 24, 2017
- Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ
April 24, 2017
- Janssen Files Japan NDA for Psoriasis Med Guselkumab
April 21, 2017
- Lecture Materials Prepared from Information Taken from Medical Charts: Bayer’s Xarelto Issue Whistleblower
April 21, 2017
- Sawai to Buy US Generic Maker Upsher-Smith
April 20, 2017
- Takeda’s “Health Innovation Park” Hoped to Bring Together Various Researchers, Other Companies Also Welcomed
April 20, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…